.Johnson & Johnson’s deprioritization of its infectious condition pipeline has actually professed another prey in the form of its own dengue infection vaccination mosnodenvir.Mosnodenvir is designed to block interactions in between pair of dengue virus healthy proteins. The injection endured J&J’s selection in 2013 to merge its transmittable ailment and injection procedures, which found the similarity a late-stage respiratory system syncytial infection program lost from the Significant Pharma’s pipe as well as an E. coli vaccination sold off to Sanofi.Mosnodenvir has had a tough time in the medical clinic, along with J&J terminating one litigation due to the effect of COVID-19 on application and stopping briefly recruitment in another research study in 2022.
However the commitment to mosnodenvir showed up to pay off in Oct 2023, when the injection was presented to generate a dose-dependent antiviral effect on the detectability and beginning of dengue virus serotype 3 in a phase 2 test. That information reduce doesn’t show up to have been enough to conserve mosnodenvir for long, along with the Big Pharma introducing this morning that it is ceasing a follow-up phase 2 industry study. The decision is connected to a “strategic reprioritization of the firm’s pandemic ailments R&D portfolio,” added J&J, which worried that no protection issues had been determined.” Johnson & Johnson will remain to assist the fight against dengue by discussing research results along with the health care community later on,” the pharma claimed in the launch.J&J had actually been actually acquiring dengue for over a years, featuring releasing a Satellite Center for Global Health Invention at the Duke-NUS Medical Institution in Singapore in 2022.
The center has actually been actually focused on increasing early-stage revelation research study to “address the developing difficulty of flaviviruses” such as dengue and also Zika.